Ozempic vs Mounjaro: Comparing the Two Most Prescribed GLP-1 Medications
| Category | Ozempic | Mounjaro |
|---|---|---|
| Active Ingredient | Semaglutide | Tirzepatide |
| Drug Class | GLP-1 receptor agonist | Dual GLP-1/GIP receptor agonist |
| Mechanism of Action | Activates GLP-1 receptors only | Activates both GLP-1 and GIP receptors (dual incretin) |
| Manufacturer | Novo Nordisk | Eli Lilly |
| FDA-Approved Indication | Type 2 diabetes; cardiovascular risk reduction in T2D | Type 2 diabetes |
| FDA Approval Year | 2017 | 2022 |
| Weight Management Brand | Wegovy (semaglutide 2.4 mg) | Zepbound (tirzepatide) |
| Dosing Frequency | Once weekly subcutaneous injection | Once weekly subcutaneous injection |
| Dose Range | 0.25 mg, 0.5 mg, 1 mg, 2 mg | 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, 15 mg |
| Maximum Dose | 2 mg once weekly | 15 mg once weekly |
| Weight Loss (Head-to-Head) | -6.2 kg (semaglutide 1 mg, SURPASS-2) | -12.4 kg (tirzepatide 15 mg, SURPASS-2) |
| HbA1c Reduction (Head-to-Head) | -1.86% (semaglutide 1 mg, SURPASS-2) | -2.46% (tirzepatide 15 mg, SURPASS-2) |
| Common Side Effects | Nausea (15-20%), diarrhea, vomiting, constipation | Nausea (12-33%), diarrhea (12-23%), vomiting, constipation |
| Cost (Without Insurance) | ~$935/month | ~$1,023/month |
| Cardiovascular Outcomes Data | SUSTAIN 6: 26% MACE reduction (in T2D); SELECT: 20% MACE reduction (via Wegovy) | SURPASS-CVOT: ongoing; no completed cardiovascular outcomes trial yet |
| Oral Formulation Available | Yes (Rybelsus — oral semaglutide for T2D) | No (injectable only) |
| Titration Duration to Max Dose | ~8-12 weeks (0.25 mg to 2 mg) | ~20 weeks (2.5 mg to 15 mg) |
| Insurance Coverage (Diabetes) | Broadly covered by most commercial and Medicare Part D plans | Broadly covered; may require step therapy after metformin |
Ozempic vs Mounjaro: The Key Differences
Ozempic (semaglutide) and Mounjaro (tirzepatide) are the two most commonly prescribed injectable medications for type 2 diabetes, and both are widely used off-label for weight management. The fundamental difference is their mechanism: Ozempic activates only GLP-1 receptors, while Mounjaro is a dual agonist that activates both GLP-1 and GIP (glucose-dependent insulinotropic polypeptide) receptors. This dual mechanism is believed to explain Mounjaro's superior efficacy in the SURPASS-2 head-to-head trial, where tirzepatide at all doses outperformed semaglutide 1 mg for both blood sugar control and weight loss in patients with type 2 diabetes. However, Ozempic has the advantage of longer real-world experience (approved 5 years earlier), completed cardiovascular outcomes data, and the availability of an oral formulation (Rybelsus).
Head-to-Head Data: The SURPASS-2 Trial
The SURPASS-2 trial is the only completed head-to-head study directly comparing tirzepatide and semaglutide. This 40-week trial randomized 1,879 adults with type 2 diabetes to tirzepatide (5, 10, or 15 mg) or semaglutide 1 mg (the Ozempic dose available at the time). The results were striking: tirzepatide 15 mg reduced HbA1c by 2.46% vs 1.86% for semaglutide 1 mg, and produced 12.4 kg of weight loss vs 6.2 kg. Even the lowest tirzepatide dose (5 mg) was numerically superior to semaglutide 1 mg for both endpoints. An important limitation: this trial compared against the Ozempic dose (max 1 mg at the time, later updated to 2 mg), not the higher Wegovy dose (2.4 mg) used specifically for weight management. A direct comparison at full weight-management doses has not been conducted.
Side Effects and Safety Comparison
Both Ozempic and Mounjaro share similar gastrointestinal side effect profiles typical of GLP-1-class medications. In the SURPASS-2 trial, nausea rates were somewhat lower with tirzepatide (12-22% across doses) compared to semaglutide 1 mg (18%), and overall discontinuation rates due to adverse events were similar (5-7% for tirzepatide vs 4% for semaglutide). Both medications carry boxed warnings about thyroid C-cell tumors and warnings about pancreatitis, gallbladder disease, and acute kidney injury. The key safety differentiator is cardiovascular outcomes data: Ozempic has completed the SUSTAIN 6 trial showing 26% MACE reduction in diabetic patients, and its sister product Wegovy completed the SELECT trial showing 20% MACE reduction in obese patients. Mounjaro's cardiovascular outcomes trial (SURPASS-CVOT) is still ongoing.
Choosing Between Ozempic and Mounjaro
For most patients with type 2 diabetes, the choice between Ozempic and Mounjaro comes down to several practical factors beyond raw efficacy numbers. Insurance coverage is often the deciding factor: check which medication your plan covers and at what tier. If both are covered equally, Mounjaro's superior glucose control and weight loss in SURPASS-2 make it an attractive first choice. However, Ozempic's completed cardiovascular outcomes data (SUSTAIN 6) provides stronger evidence for cardiovascular risk reduction in diabetic patients. If injections are a concern, Ozempic offers a pathway to oral semaglutide (Rybelsus) that does not require injections. If maximizing weight loss is a priority, Mounjaro (or its weight-management counterpart, Zepbound) has produced the largest average weight reductions in clinical trials. Both medications require the same lifestyle foundations: a balanced, protein-rich diet, regular resistance training, and adequate hydration.
- Check insurance formulary coverage for both before deciding
- If cardiovascular risk is a primary concern, Ozempic has stronger outcomes data
- If maximizing weight loss is the priority, Mounjaro has shown greater efficacy
- If you prefer avoiding injections long-term, Rybelsus (oral semaglutide) is an option
- Both require the same lifestyle modifications for optimal results
- Switching from one to the other is possible if the first is inadequate
Medical Disclaimer
This content is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting, stopping, or changing any medication. Individual results may vary.
Frequently Asked Questions
In the SURPASS-2 head-to-head trial, tirzepatide (Mounjaro) produced twice the weight loss of semaglutide 1 mg (Ozempic) — 12.4 kg vs 6.2 kg over 40 weeks. Cross-trial comparisons of the weight-management versions (Zepbound vs Wegovy at full doses) also suggest tirzepatide produces greater average weight loss (22.5% vs 14.9%). However, individual responses vary and some patients do better on one medication than the other.
Yes. Switching is common, especially for patients who have plateaued on Ozempic or desire greater weight loss. No washout period is required. Most prescribers start Mounjaro at the 2.5 mg initiation dose regardless of your previous Ozempic dose. Expect potential GI side effects during the transition, similar to when you first started Ozempic. A new prior authorization will likely be needed from your insurer.
Both medications have similar safety profiles with the same class warnings (thyroid C-cell tumors, pancreatitis, gallbladder disease). Ozempic has the advantage of longer real-world experience (on the market since 2017 vs 2022 for Mounjaro) and completed cardiovascular outcomes trials (SUSTAIN 6, SELECT). GI side effects appear comparable in head-to-head data. Neither has been shown to be significantly safer than the other in clinical trials.
Several reasons are possible: your insurance may cover Ozempic but not Mounjaro, your plan may require trying a GLP-1 agonist before a dual agonist (step therapy), your doctor may prefer the longer safety track record of Ozempic, or the cardiovascular risk reduction data from SUSTAIN 6 may be relevant to your clinical situation. If you are interested in Mounjaro, ask your prescriber about the rationale and whether switching would be appropriate.
Yes, the side effect profiles are very similar. Both cause primarily GI symptoms (nausea, diarrhea, vomiting, constipation) and carry the same boxed warning about thyroid C-cell tumors. Both have warnings for pancreatitis, gallbladder disease, and acute kidney injury. In SURPASS-2, nausea rates were comparable (12-22% for tirzepatide vs 18% for semaglutide), and discontinuation rates were similar. Most patients tolerate both medications well after the initial dose escalation period.
List prices are similar: Ozempic is approximately $935/month and Mounjaro approximately $1,023/month. Actual costs depend on insurance coverage and manufacturer savings programs. Novo Nordisk (Ozempic) and Eli Lilly (Mounjaro) both offer copay assistance cards for commercially insured patients. Eli Lilly has also introduced cash-pay Zepbound vials at $399-$549/month. Always compare your specific out-of-pocket cost for both before choosing.